Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 12 (11), 866-85

Glycine Transporters as Novel Therapeutic Targets in Schizophrenia, Alcohol Dependence and Pain

Affiliations
Review

Glycine Transporters as Novel Therapeutic Targets in Schizophrenia, Alcohol Dependence and Pain

Robert J Harvey et al. Nat Rev Drug Discov.

Abstract

Glycine transporters are endogenous regulators of the dual functions of glycine, which acts as a classical inhibitory neurotransmitter at glycinergic synapses and as a modulator of neuronal excitation mediated by NMDA (N-methyl-D-aspartate) receptors at glutamatergic synapses. The two major subtypes of glycine transporters, GlyT1 and GlyT2, have been linked to the pathogenesis and/or treatment of central and peripheral nervous system disorders, including schizophrenia and related affective and cognitive disturbances, alcohol dependence, pain, epilepsy, breathing disorders and startle disease (also known as hyperekplexia). This Review examines the rationale for the therapeutic potential of GlyT1 and GlyT2 inhibition, and surveys the latest advances in the biology of glycine reuptake and transport as well as the drug discovery and clinical development of compounds that block glycine transporters.

Similar articles

See all similar articles

Cited by 44 PubMed Central articles

See all "Cited by" articles

References

    1. Trends Genet. 2008 Sep;24(9):439-47 - PubMed
    1. Eur J Neurosci. 2009 Sep;30(6):1077-91 - PubMed
    1. Nature. 1989 Mar 30;338(6214):377-8 - PubMed
    1. Front Psychiatry. 2011 Mar 07;2:8 - PubMed
    1. Neurology. 1981 Jul;31(7):872-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback